US$10 million milestone payment to HUTCHMED follows first national reimbursement in Europe —— Follows June 2024 European approval of FRUZAQLA® ...
Recursion on Tuesday held a webinar to discuss results from the Phase 1/2 study of REC-617, a selective CDK7 inhibitor, in advanced solid tumors. The results were presented at an AACR Special ...
MedPage Today on MSN2d
Sticking With CDK4/6 Inhibitors for Breast Cancer Wins in Post-Progression SettingOpens in a new tab or window Patients with advanced estrogen receptor (ER)-positive breast cancer that progressed on CDK4/6 inhibitors ... "We're not really sure about the right sequence. We don't ...
Repare Therapeutics (RPTX) reported positive data from its MYTHIC Phase 1 gynecologic expansion clinical trial evaluating the combination of ...
Healthcare Asia on MSN9d
Tam Anh General Hospital named international research site for RBS2418The initiative will include local biomarker testing. Vietnam’s Tam Anh General Hospital has been designated as the first ...
Head and neck cancer comprises a group of biologically similar cancers that start in the lip, oral cavity (mouth ... indicating a need for biomarkers that enable accurate predictions of a ...
A study, published in BME Frontiers, introduces a novel approach to cancer biomarker detection using ... bladder cancer, and oral squamous cell carcinoma (OSCC). However, traditional methods ...
Hosted on MSN10d
New Hope For Women With Advanced ER+/HER2- Breast Cancer: The Drug Imlunestrant Shows Significant BenefitResults of the a phase III clinical trial called EMBER-3 indicate the promise and efficacy of a drug called imlunestrant. This is a new kind of oral selective estrogen receptor degrader (SERD), used ...
Vivoryon Therapeutics N.V. Reports Q3 2024 Results and Highlights Progress on Varoglutamstat in Kidney Disease Varoglutamstat Phase 2 program shows highly consistent, statistically significant and cli ...
10d
Imlunestrant, an investigational next-generation selective estrogen receptor degrader (SERD), improved progression-free ...
It looks like Eli Lilly’s oral selective estrogen receptor degrader (SERD) imlunestrant may need some extra help to reach a ...
A groundbreaking international study has found that imlunestrant plus abemaciclib significantly improved progression-free survival (PFS) versus imlunestrant monotherapy in patients with estrogen ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback